Solid Biosciences heads into its May 19 quarterly report with shorts retreating from a recent peak yet the stock still carrying one of the more elevated short positions in the gene therapy space.
Short sellers have been trimming exposure at a notable pace. Short interest as a percentage of the free float fell from roughly 17.1% on April 23 — the highest reading of the past six weeks — down to 13.9% by May 12. That's a drop of nearly two percentage points in a single week, mirroring the stock's 11.9% gain over the same period to $7.72. The direction is clear: shorts covered as the price rallied, not after it. What's less clear is whether that exit reflects genuine conviction change or simply risk reduction ahead of a binary event.
The borrow market tells a story of abundant supply, not squeeze pressure. Cost to borrow is running near 0.49% — essentially the floor — and availability remains loose, with the lending pool well stocked relative to outstanding short interest. Borrow availability has held far above tight territory throughout the past month, meaning new short positions can be initiated cheaply and easily. The options market echoes that relaxed tone: the put/call ratio is 0.63, barely above its 20-day average of 0.57 and only 0.45 standard deviations elevated. There's no sign of aggressive hedging or speculative put-buying building ahead of the earnings date. Positioning looks cautious rather than crowded.
The Street is firmly bullish — and two fresh notes this week reinforced that bias from different directions. Piper Sandler raised its target to $18 from $17 while maintaining Overweight, while Wedbush nudged its target slightly lower to $16 from $17 but held its Outperform rating. Both moves landed on May 13, the day after what appears to be a pre-earnings update in the data. The consensus mean target sits at $17.15 against a $7.72 close, implying roughly 122% upside on the analyst aggregate — though the wide range, from $12 at JPMorgan up to $26 at Guggenheim (which initiated in March), reflects genuine disagreement about timing and clinical execution rather than directional confusion. The bull case centres on SGT-003 for Duchenne muscular dystrophy and the dual neurological and cardiac profile of SGT-212, both carrying FDA Orphan Drug and Fast Track designations. Bears point to the lack of approved gene therapy precedent in this exact space, manufacturing risk, and the long road from interim data to commercialisation.
Institutional ownership has been shifting in ways worth noting. RA Capital added over 3.1 million shares in the period ending March 17, lifting its stake to 9.1% of shares outstanding. Vestal Point Capital added 3.5 million shares to reach 6.9%. Both are specialist healthcare funds with deep gene therapy knowledge. Against that, Bain Capital Life Sciences trimmed its position by 3.4 million shares to 4.6% — a meaningful reduction from a house that has owned SLDB for years and will be read carefully by the market. The net insider position over the past 90 days is technically a small net positive, but that's almost entirely explained by routine equity awards; the February executive sells — led by CEO Bo Cumbo offloading 16,644 shares at $5.82 — were standard withholding transactions at a price well below current levels.
The reaction history ahead of May 19 is thin but instructive. The prior two events produced muted one-day moves of roughly -1.5% and +0.3%, followed by a wide five-day divergence: -0.14% after one and +8.6% after the other. The stock has not established a reliable post-earnings directional pattern at this stage of its clinical lifecycle. With short interest still above 13% of the float, costs to borrow still low, and the balance of analyst opinion firmly bullish, the print on May 19 is less about the score and more about what management says regarding SGT-003 dosing data and the SGT-212 regulatory timeline.
See the live data behind this article on ORTEX.
Open SLDB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
